Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
OrganoClick AB's Enterprise Value for the quarter that ended in Mar. 2026 was €16.67 Mil.
OrganoClick AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrganoClick AB EV-to-EBIT Related Terms
OrganoClick AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for OrganoClick AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, OrganoClick AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrganoClick AB EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, OrganoClick AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where OrganoClick AB's EV-to-EBIT falls into.
OrganoClick AB's current Enterprise Value is €15.09 Mil.
OrganoClick AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrganoClick AB (FRA:0CF) has a EV-to-EBIT of -5.66 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OrganoClick AB and its competitors. According to the industry distribution chart, OrganoClick AB ranks #999999 out of 1241 companies in the Chemicals industry.
Is OrganoClick AB's EV-to-EBIT too high?
OrganoClick AB's current EV-to-EBIT is -5.66. Based on the distribution chart, OrganoClick AB ranks #999999 out of 1241 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, OrganoClick AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does OrganoClick AB's EV-to-EBIT compare to LIN and SHW?
According to the Chemicals industry distribution chart, OrganoClick AB ranks #999999 out of 1241 companies for EV-to-EBIT. This places OrganoClick AB in the lower half of its industry. The industry median EV-to-EBIT is 16.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 16.86, based on 1,241 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OrganoClick AB and its competitors. For the Chemicals industry, the median EV-to-EBIT is 16.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrganoClick AB's current EV-to-EBIT is -5.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrganoClick AB stock overvalued right now?
OrganoClick AB (FRA:0CF) has a current EV-to-EBIT of -5.66. The stock's GF Value™ is €0.16, compared to a current price of €0.03 — trading 82.1% below its estimated fair value. The current EV-to-EBIT is -5.66. OrganoClick AB's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OrganoClick AB (FRA:0CF), the current EV-to-EBIT is -5.66 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrganoClick AB (FRA:0CF) Overvalued in 2026?
Based on GuruFocus' analysis, OrganoClick AB stock appears to be undervalued.
The current stock price of €0.03 is trading 82.1% below its estimated GF Value™ of €0.16.
Key valuation signals for FRA:0CF:
EV-to-EBIT: -5.66
GF Value™: €0.16 vs. price of €0.03 (82.1% below fair value)
No single metric tells the full story. See the FRA:0CF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrganoClick AB is involved in the chemicals industry. Its product portfolio includes green chemical technologies for creating water repellency, biobased binders for increasing the mechanical strength, and wood treatment products for resistance to fungal degradation and resistance to fire. It operates in four business areas Functional Wood, Green coatings & maintenance products, Nonwoven & technical textile, and Other. The group has a single operating segment.
25GF Score
Get the complete analysis for FRA:0CF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0CF has been successfully added to your 
